A spokesperson from ANSTO has provided a statement
Technetium-99m (Tc-99m) is used in hospitals around the world to diagnose a variety of heart, lung and musculoskeletal conditions, as well as cancers. It is the most common nuclear medicine, with global demand estimated to be up to 40 million doses a year, produced by experts with a small network of 11* nuclear reactors worldwide.
Australia is making a significant global contribution by stepping up to help prevent a shortfall in world nuclear medicine supplies with two projects worth about $170 million.
Director-General of the IAEA, Yukiya Amano visited Lucas Heights and inspected progress on the ANSTO Nuclear Medicine production facility, which is in the final phases of construction.
An update on Synroc, an Australian innovation to store nuclear waste from nuclear medicine production
We have uploaded a short timelapse video of the concrete pour for shielding of the Mo-99 hot cells.
Australia's new Prime Minister Malcolm Turnbull has made the Hon Christopher Pyne MP the Minister for, Industry, Innovation and Science.
ANSTO has just delivered its four millionth dose of nuclear medicine, used to diagnose a wide range of illnesses, including cardiac conditions, cancers and skeletal injuries that will benefit one in every two Australians at some point during their lifetime.
Australia’s new nuclear medicine manufacturing facility is taking shape – a project which will enable Australia to help meet world demand for the most common radionuclide used in nuclear medicine, Molybdenum-99.
You can’t see it, hear it or smell it, and it’s constantly changing: but despite that, Australia’s nuclear scientists have figured out how to more accurately measure the unit of activity for radionuclides, the Becquerel (Bq).